Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by NKGen Biotech NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference October 29, 2024 From NKGen Biotech Via GlobeNewswire Tickers NKGN NKGen Biotech Announces Upcoming Presentation at the 16th World Stroke Congress (WSC 2024) October 15, 2024 From NKGen Biotech Via GlobeNewswire Tickers NKGN NKGen Biotech Announces Poster Presentations at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference October 08, 2024 From NKGen Biotech Via GlobeNewswire Tickers NKGN NKGen Biotech’s Positive Phase 1 Clinical Data in Moderate Alzheimer’s Disease Advances Troculeucel into Phase 2 with First Patient Dosed in Phase 1/2a Trial September 12, 2024 From NKGen Biotech Via GlobeNewswire Tickers NKGN NKGen Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 03, 2024 From NKGen Biotech Via GlobeNewswire Tickers NKGN NKGen Biotech Presents New Positive SNK01 Biomarker Data at the 2024 Alzheimer’s Association International Conference July 30, 2024 From NKGen Biotech Via GlobeNewswire Tickers NKGN NKGen Biotech to Present New Positive SNK01 Clinical Trial Biomarker Data at the 2024 Alzheimer’s Association International Conference July 18, 2024 From NKGen Biotech Via GlobeNewswire Tickers NKGN NKGen Biotech Appoints Dr. Marco Gottardis to its Board of Directors July 15, 2024 From NKGen Biotech Via GlobeNewswire Tickers JNJ NKGN NKGen Biotech Presents Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy for Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024 June 12, 2024 From NKGen Biotech Via GlobeNewswire Tickers NKGN NKGen Biotech to Present at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting May 02, 2023 From NKGen Biotech Via GlobeNewswire NKGen Biotech, Inc. to Become Publicly Traded Company via Business Combination with Graf Acquisition Corp. IV April 14, 2023 From NKGen Biotech Via GlobeNewswire Tickers GFOR NKGen Biotech Announces Formation of Scientific Advisory Board to Drive its Pipeline Strategy for Natural Killer Cell Therapies Targeting Neurodegenerative Diseases March 08, 2023 From NKGen Biotech Via GlobeNewswire NKGen Biotech Appoints Paul Y. Song, MD as Chief Executive Officer January 10, 2023 From NKGen Biotech Via GlobeNewswire NKGen Biotech Announces Collaboration with the Parkinson’s Foundation to Bring Its Novel Natural Killer Cell Therapy to the Clinic for Advanced Parkinson’s Disease November 04, 2022 From NKGen Biotech Via GlobeNewswire NKGen Biotech Receives IND Clearance from FDA for SNK02 Allogeneic Natural Killer Cell Therapy for Solid Tumors October 17, 2022 From NKGen Biotech Via GlobeNewswire Stock Quote API & Stock News API supplied by www.cloudquote.io Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
